DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for REM sleep behavior disorder — screening already-approved drugs against its 7-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleREM sleep behavior disorder maps to a 7-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for rem sleep behavior disorder is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
growth arrest specific 1 (GAS1) — GAS1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet clrdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7RHQ · 3.53 Å · ligand CHOLESTEROL (CLR). Experimental structure, not a prediction.
What the evidence adds up to
A 2015 case report describes a sixty-five-year-old man with a twelve-year history of acting out violent dreams, causing injury to himself and his spouse. Diagnosis of idiopathic REM sleep behaviour disorder (RBD) was made on clinical features after excluding neurodegenerative causes, without sleep studies. The patient showed marked response to treatment with clonazepam 2 mg daily. A 2022 overview of RBD discusses the history, pathophysiology, clinical aspects, diagnostic issues, and biomarkers, with a focus on European contributions, but provides no new trial data or quantitative outcomes.
A 2009 rat study examined adenosine receptors in the basal forebrain in relation to sleep homeostasis. Infusion of an A1 receptor antagonist during sleep deprivation significantly reduced recovery non-REM sleep amount and delta power, while an A2A receptor antagonist had no effect. The authors concluded that adenosine promotes recovery non-REM sleep through A1 receptors in the basal forebrain. This work is preclinical and does not address RBD directly.
No controlled trials, response rates, or survival data for any drug in RBD are reported in these abstracts. The only treatment mentioned is clonazepam in a single case. What remains missing are randomised controlled trials with adequate sample sizes, validated biomarkers for patient stratification, and funding for prospective studies that can distinguish idiopathic RBD from prodromal neurodegeneration.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Sleep Research · 2022 · 31 citations · open access
Rapid eye movement sleep behaviour disorder: Past, present, and future
AbstractThis manuscript presents an overview of REM sleep behaviour disorder (RBD) with a special focus on European contributions. After an introduction examining the history of the disorder, we address the pathophysiological and clinical aspects, as well as the diagnostic issues. Further, implications of RBD diagnosis and biomarkers are discussed. Contributions of European researchers to this field are highlighted.
The role of the basal forebrain adenosine receptors in sleep homeostasis
AbstractMultiple studies indicate that adenosine released in the basal forebrain during prolonged wakefulness could affect recovery sleep. It is still unclear which of adenosine receptors provide its sleep-modulating effects in the basal forebrain. We infused adenosine A1 and A2A receptors antagonists into the rat basal forebrain during sleep deprivation and compared characteristics of recovery non-rapid eye movement (non-REM) sleep (its amount and non-REM sleep delta power) after sleep deprivation, and after sleep deprivation combined with perfusion of antagonists. A1 receptor antagonist significantly reduced recovery sleep amount and delta power, whereas A2A receptor antagonist had no effect on recovery sleep. We conclude that adenosine can promote recovery non-REM sleep when acting through A1 receptors in the basal forebrain.
Sri Lanka Journal of Psychiatry · 2015 · 0 citations · open access
REM sleep behaviour disorder: The stuff of dreams
AbstractWe describe the case of a sixty-five year old male presenting with acting out his violent dreams over a period of twelve years, causing injury to himself and his spouse. His case was not conducive to sleep studies, and the diagnosis of idiopathic REM sleep behaviour disorder was made on positive clinical features and exclusion of possible neurodegenerative aetiologies. He showed marked response to treatment with a daily dose of clonazepam 2mg.SL J Psychiatry 2015; 6(2) 30-32
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
